- Home
- Product Information
- CB2 Agonist
| Compound Code | RQ-00202730 |
|---|---|
| Primary Target Indications | Irritable bowel syndrome |
| Development Stage | Discovery research Portfolio for global development, manufacturing, and marketing rights |
| Product Summary | The CB2 receptor selective agonist does not have the side effects of cannabinoids and shows superior analgesic effect on gastrointestinal tract hypersensitivity and inflammatory pain. At RaQualia Pharma, we are pursuing a project to obtain a development candidate compound that has a singular effect on the CB2 receptor. We are identifying in animal models compounds that will be able to treat IBS by providing greater pain relief for abdominal pain and controlling the acceleration of bowel movements due to stress. |
| Non-Confidential Materials |
